PLK1/BRD4-IN-5

PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC50 values of 0.3 nM and 60.8 nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research[1].

Product Specifications

CAS Number

[3063893-60-4]

UNSPSC

12352005

Target

Apoptosis; Epigenetic Reader Domain; Polo-like Kinase (PLK)

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/plk1-brd4-in-5.html

Concentration

10mM

Purity

99.55

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC[C@@H]1C(N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C5C(CCN5C(CN6C[C@@H](N[C@@H](C6)C)C)=O)=C4)OC)C)=O

Molecular Formula

C31H44N8O3

Molecular Weight

576.73

References & Citations

[1]Liu J, et al. Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer. Bioorg Med Chem. 2024;101:117